Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Hematopoietic cell transplantation for Waldenström macroglobulinemia

Bone Marrow Transplantation volume 47, pages 330–336 (2012)Cite this article

Abstract

Waldenström macroglobulinemia (WM) is a distinct indolent B-cell lymphoproliferative malignancy characterized by IgM paraproteinemia. Although the disease is sensitive to chemo-immunotherapy, it remains incurable and affected patients have a median survival of 5–10 years. Risk stratification in newly diagnosed patients should start with a prognostic evaluation based on the International Prognostic Scoring System for WM (IPSSWM) to identify those patients in whom particularly poor survival with chemotherapy is expected and in whom alternative treatment strategies, such as hematopoietic cell transplantation (HCT), should be considered. High-dose chemotherapy followed by autologous HCT (auto-HCT) results in disease-free survival of 45–65% at 5 years, but is unlikely to be curative. Chemosensitive disease at the time of auto-HCT is the most important prognostic factor for response rate and overall survival. Allogeneic donor HCT may offer a unique immune-mediated GVL effect with a plateau in relapse rates and potential for extended disease-free survival. The risk of allogeneic HCT complications is justified in HCT-eligible patients whose expected survival is <5 years. Here, we present the advances in non-transplant strategies and the therapeutic role of transplant, and suggest a treatment algorithm for selecting a HCT strategy while adhering to current evidence supporting autologous and allogeneic donor HCT for WM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP . Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23: 1564–1577.

    Article  Google Scholar 

  2. Swerdlow S, Campo E, Nea H (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer: Lyon, France, 2008, p 194. ISBN 978-92-832-2431-0.

    Google Scholar 

  3. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinico-pathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semic Oncol 2003; 30: 110–115.

    Article  Google Scholar 

  4. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V et al. Update on treatment recommendations from the fourth international workshop on Waldenstrom's macroglobulinemia. J Clin Oncol 2009; 27: 120–126.

    Article  Google Scholar 

  5. Treon SP . How I treat Waldenstrom macroglobulinemia. Blood 2009; 114: 2375–2385.

    Article  CAS  Google Scholar 

  6. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113: 4163–4170.

    Article  CAS  Google Scholar 

  7. Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 2010; 34: 1340–1343.

    Article  CAS  Google Scholar 

  8. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1408–1414.

    Article  CAS  Google Scholar 

  9. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1422–1428.

    Article  CAS  Google Scholar 

  10. Rourke M, Anderson KC, Ghobrial IM . Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma 2010; 51: 1779–1792.

    Article  Google Scholar 

  11. Vijay A, Gertz MA . Waldenstrom macroglobulinemia. Blood 2007; 109: 5096–5103.

    Article  CAS  Google Scholar 

  12. Anagnostopoulos A, Aleman A, Giralt S . Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. Semin Oncol 2003; 30: 286–290.

    Article  Google Scholar 

  13. Dreger P, Glass B, Kuse R, Sonnen R, von Neuhoff N, Bolouri H et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 1999; 106: 115–118.

    Article  CAS  Google Scholar 

  14. Munshi NC, Barlogie B . Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 282–285.

    Article  CAS  Google Scholar 

  15. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N et al. Transplantation in Waldenstrom's macroglobulinemia--the French experience. Semin Oncol 2003; 30: 291–296.

    Article  CAS  Google Scholar 

  16. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845–854.

    Article  Google Scholar 

  17. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 2008; 13: 119–127.

    Article  Google Scholar 

  18. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227–2232.

    Article  CAS  Google Scholar 

  19. Dreger P, Schmitz N . Autologous stem cell transplantation as part of first-line treatment of Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2007; 13: 623–624.

    Article  Google Scholar 

  20. Caravita T, Siniscalchi A, Tendas A, Cupelli L, Dentamaro T, Natale G et al. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2009; 43: 587–588.

    Article  CAS  Google Scholar 

  21. Stakiw J, Kim DH, Kuruvilla J, Gupta V, Messner H, Lipton JH . Evidence of graft-versus-Waldenstrom's macroglobulinemia effect after allogeneic stem cell transplantation: a single centre experience. Bone Marrow Transplant 2007; 40: 369–372.

    Article  CAS  Google Scholar 

  22. Maloney DG . Evidence for GWM following mini-allo in WM. Presented at the Fifth International Workshop for Waldentrom's Macroglobulinemia; Stockholm, 2008 (abstract 147).

  23. Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 2010; 95: 950–955.

    Article  Google Scholar 

  24. Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4926–4934.

    Article  Google Scholar 

  25. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85: 824–833.

    Article  Google Scholar 

Download references

Acknowledgements

We appreciate the editorial assistance of Michael Franklin and Carol Taubert.

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN, USA

    V Bachanova & L J Burns

Authors
  1. V Bachanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L J Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Bachanova.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bachanova, V., Burns, L. Hematopoietic cell transplantation for Waldenström macroglobulinemia. Bone Marrow Transplant 47, 330–336 (2012). https://doi.org/10.1038/bmt.2011.105

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.105

Keywords

This article is cited by

Search

Advanced search

Quick links